Technical note: identifying the prostate cancer ‘superscan’ by quantitative skeletal scintigraphy

Nuclear Medicine Communications

Volumn 29, Issue 7, 2008, Pages 654-659

  Hawkins, Terry ^a   Halewood, Mary M ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Prostate cancer; Radionuclide bone scan; Skeletal scintigraphy; Superscan

Indexed keywords

ADULT; ARTICLE; BONE TUMOR; COMPUTER ASSISTED DIAGNOSIS; HUMAN; IMAGE ENHANCEMENT; MALE; METASTASIS; METHODOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; BLADDER FUNCTION; BONE SCINTISCANNING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; IMAGE ANALYSIS; IMAGE PROCESSING; MAJOR CLINICAL STUDY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SCINTILLATION CAMERA; STATISTICAL SIGNIFICANCE; WHOLE BODY SCINTISCANNING;

ADULT; BONE NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

ETIDRONIC ACID TC 99M;

EID: 49649119976     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f8140c     Document Type: Article

References (19)

1. Manyak MJ, Javitt MC. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urolog Oncol 1998; 16:145-152.
2. m-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases. Am J Roentgenol 1975; 125:972-977.
3. Constable AR, Cranage RW. Recognition of the superscan in prostatic bone scintigraphy. Br J Radiol 1981; 54:122-125.
4. Fogelman I, McKillop JH, Boyle IT, Greig WR. Absent kidney sign associated with symmetrical and uniformly increased uptake of radiopharmaceutical by the skeleton. Eur J Nucl Med 1977; 2:257-259.
5. Anscombe A, Walkden SB. An interesting bone scan in multiple myeloma-myeloma superscan. Br J Radiol 1983; 56:489-492.
6. Wilson MA, Calhoun FW, Gaines J, Goldsmith SJ. Patterns of diffusely increased skeletal radiopharmaceutical uptake. Australas Radiol 1981; 25:177-180.
7. Buckley O, O'Keefe S, Geoghegan T, Lyburn ID, Munk PL, Worsley D, et al. Tc99m bone scintigraphy suoperscans: a review. Nucl Med Commun 2007; 28:521-527.
8. Fukuda T, Inoue Y, Ochi H, Nakazima H, Sawa H, Onoyama Y. Abnormally high diffuse activity on bone scintigram. The importance of exposure time for its recognition. Eur J Nucl Med 1982; 7:275-277.
9. Blake GM, Park-Holohan SJ, Cook GJR, Fogelman I. Quantitative studies of bone with 18F-Fluoride and 99mTc-Methylene Diphosphonate. Semin Nucl Med 2001; 1:28-49.
10. Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 2003; 92:379-383.
11. Basu S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 2004; 93:889.
12. Ohashi K, Smith HS, Jacobs MP. ‘Superscan’ appearance in distal renal tubular acidosis. Clin Nucl Med 1991; 16:318-320.
13. Liu RS, Chu YK, Chu LS, Yeh SH, Yen SH, Chen KY, et al. Superscan in patients with nasopharyngeal carcinoma. Clin Nucl Med 1996; 21:302-306.
14. Swislocki ALM, Barnett CA, Darnell PBS, Noth RH. Hyperthyroidism: an under appreciated cause of diffuse bone disease. Clin Nucl Med 1998; 23:241-243.
15. Berna L, Torres G, Carrio I, Estorch M, Germa JR, Alonso C. Antigranulocyte antibody bone marrow scans in cancer patients with metastatic bone superscan appearance. Clin Nucl Med 1994; 19:121-128.
16. Basu S, Nair N, Awasare S, Tiwari BP, Asopa R, Nair C. Tc99m (V) DMSA scintigraphy in skeletal metastases and superscans arising from various malignancies; diagnosis, treatment monitoring and therapeutic implications. Br J Radiol 2004; 77:347-361.
17. Yuksel D, Ilgan S, Arslan N, Ugur O, Ozturk E, Bayhan H. The role of Tc99m (V) DMSA scintigraphy in the evaluation of superscan on bone scintigraphy. Clin Nuc Med 2000; 25:193-196.
18. Nisbet AP, Shaw PJ, Blackford N, Edwards S, Fogelman I, Lazarus C, et al. A single plasma sample method to assess disease activity in patients with bone metastases from carcinoma of the prostate. B J Urol 1986; 58:545-548.
19. Fogelman I, Bessent RG, Gordon D. A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease. Eur J Nucl Med 1981; 6:93-97.